Catalina Alamon

Montevideo, MO 11400, Uruguay

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration.

A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration.

Journal: Molecular pharmaceutics

Published: April 04, 2023

Substrate Recognition Properties from an Intermediate Structural State of the UreA Transporter.

Substrate Recognition Properties from an Intermediate Structural State of the UreA Transporter.

Journal: International journal of molecular sciences

Published: November 10, 2022

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease.

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease.

Journal: Science advances

Published: September 21, 2022

Exploring the cell death mechanisms of cytotoxic [1,2,3]triazolylcarborane lead compounds against U87 MG human glioblastoma cells.

Exploring the cell death mechanisms of cytotoxic [1,2,3]triazolylcarborane lead compounds against U87 MG human glioblastoma cells.

Journal: Chemical biology & drug design

Published: September 16, 2022

The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS.

The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS.

Journal: Acta neuropathologica communications

Published: August 03, 2021

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity.

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity.

Journal: Cancers

Published: October 21, 2020

Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer.

Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: June 20, 2020

Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.

Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.

Journal: Cells

Published: May 01, 2020

Carboranylanilinoquinazoline EGFR-inhibitors: toward 'lead-to-candidate' stage in the drug-development pipeline.

Carboranylanilinoquinazoline EGFR-inhibitors: toward 'lead-to-candidate' stage in the drug-development pipeline.

Journal: Future medicinal chemistry

Published: October 05, 2019

Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment.

Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: November 01, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026